Months into booming acute migraine launch, Biohaven chases prevention with oral CGRP med Nurtec ODT

Kyle Blankenship

In the suddenly bustling market for CGRP acute migraine fighters, Biohaven has touted its Nurtec ODT as an obvious choice for patients with its fast …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Months into booming acute migraine launch, Biohaven chases prevention with oral CGRP med Nurtec ODT

Kyle Blankenship

Sign up to read this article for free.

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

CagriSema’s weight loss data disappointed. What does Novo do next?

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

CMS explains what went into its first round of drug price negotiations

Months in­to boom­ing acute mi­graine launch, Bio­haven chas­es pre­ven­tion with oral CGRP med Nurtec ODT

Kyle Blankenship

Sign up to read this article for free.

more like this

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Months into booming acute migraine launch, Biohaven chases prevention with oral CGRP med Nurtec ODT

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

CagriSema’s weight loss data disappointed. What does Novo do next?

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

CMS explains what went into its first round of drug price negotiations